Innovation4Alpha

Innovation4Alpha

Innovation4Alpha is a podcast dedicated to the intersection of finance, technology, leadership and healthcare innovation with the goal of both entertainment and education for our community.

MRG Health: Chronic Care Management on a New Level (226)
Jul 16 2022
MRG Health: Chronic Care Management on a New Level (226)
MRG address issues involving access to care, chronic disease management, patient adherence & compliance to doctors orders, and frees up clinicians time through leveraging technology so they can better monitor and manage larger amounts of patients more effectively and efficiently.Smart Care 360 is a complete and comprehensive care management platform that allows physicians and caregivers to manage the full continuum of care. By continuous monitoring of a patient’s vitals, nutrition, medication, and daily living activities clinicians see a holistic picture of the patient. Using their AI and threshold capabilities they provide a more proactive approach for care decisions and can alert caregivers to any change in condition. The platform is a complete solution that includes auto messaging, reminders to patients, 2 way communication, video conferencing with vitals displayed in real time -- all recorded and integrated into any EMR. With MRG Care 360, there is a single view of everything on a patient, with alerts, thresholds, and continuous access for patients and physicians to each other. The MRG real-time RPM Management Solution increases staffing efficiency, reduces doctor and nurse burnout and provides more patient info with instant access to the patients and staff. The platform was developed after 2+ years of R&D, and being involved in 4 very in depth Texas based studies on major clinical / operational needs in specific specialties & chronic diseases throughout rural, urban, and metro geographic regions. The data was compiled, and prioritization of our capabilities was built on a code-less drag and drop UX/UI with decision tree logic that allows simple patient planning, customization and flexibility based on the HCO's needs which also promotes efficient and scalable deployment solutions for large variable patient groups based on the specific specialty, disease, or vertical market needs.
Neobe: Battling Cancer With Safe Bacteria (220)
May 31 2022
Neobe: Battling Cancer With Safe Bacteria (220)
Neobe Therapeutics is an early-stage startup engineering safe recombinant bacterial products to enable immune infiltration in solid tumors. Their bacterial products combine innate tumor colonization with genetically engineered inducible biosensors to disrupt tumor microenvironment barriers to infiltration. By enabling successful infiltration of immune excluded tumors using our bacterial products they will be able to multiply the number of patients that respond to existing immunotherapies, with a focus on checkpoint inhibitors. Neobe was formed in January 2021 in London, UK with the support of Deep Science Ventures and Cancer Research UK. The founding team is made up of Dr. Pedro Correa de Sampaio, a cancer biologist with a successful career studying the tumor microenvironment in top academic institutions in the UK and the US; and Dr. Annelise Soulier, a microbiologist and molecular biologist with several years of experience engineering bacteria for therapeutic applications in one of the top UK companies in the field, having authored patents in the field and developed products that are currently in clinical trials. The founding team has the support of a world class advisory board, including top academic researchers and former C-level industry executives in the field. It was selected for the 2021 cohort of the highly prestigious Accelerate@Babraham in Cambridge, UK, won the London branch of the Imagine IF! healthcare startup competition and Neobe's co-founder Annelise Soulier was a finalists of the AIM-HI Women's Venture Competition. During its first year, Neobe developed the genetic tools necessary for the generation of its initial prototype, and established collaborations with top academic institutions such as the Barts Cancer Institute to initiate efficacy studies. Neobe was also recently awarded a collaborative Innovate UK Biomedical Catalyst grant, from the UK government, for the development of its second product at a total project cost of £505K.